Researchers tested two smoking cessation approaches for 1,357 adult
smokers who were hospitalized and expressed a desire to quit.
Patients were randomly assigned to receive a free supply of an
approved smoking cessation aid or to join a control group that could
call a phone hotline for cessation advice.
Overall, 28 percent of participants occasionally used e-cigarettes
within three months after discharge.
Six months after they left the hospital, about 10 percent of people
who reported using e-cigarettes over the first three months after
discharge had successfully quit smoking traditional cigarettes,
compared with 27 percent of those not using e-cigarettes, lab tests
found.
While this study wasn’t designed to prove whether or how
e-cigarettes might directly impact the chance of smoking cessation,
it does suggest that occasional e-cigarette use, which was common
among study participants, may not help this effort, said lead study
author Dr. Nancy Rigotti, a researcher at Harvard Medical School and
director of the Tobacco Research and Treatment Center at
Massachusetts General Hospital in Boston.
“The study is consistent with the hypothesis that smokers need to
use e-cigarettes regularly and daily and switch completely from
cigarettes to e-cigarettes for them to have the greatest chance of
help,” Rigotti, who has received research funding from Pfizer, maker
of the smoking-cessation drug Chantix, said by email.
Big U.S. tobacco companies are all developing e-cigarettes. The
battery-powered gadgets feature a glowing tip and a heating element
that turns liquid nicotine and flavorings into a cloud of vapor that
users inhale.
When e-cigarettes contain nicotine, they can be addictive like
traditional cigarettes. Even without nicotine, earlier research
suggests that flavorings and other ingredients in e-liquids used for
vaping could be linked to serious breathing problems.
A big question about e-cigarettes, namely, whether they’re safe or
at least safer than traditional cigarettes, isn’t answered by the
current study.
Many smokers who attempt to quit fail, regardless of what cessation
aid they try, and a separate study offers fresh evidence that even
medications aren’t a fool-proof tool.
[to top of second column] |
For this study, researchers randomly assigned 302 smokers
hospitalized with heart problems to receive either varenicline (Chantix)
or a placebo pill for 12 weeks, in addition to counseling.
One year later, lab tests showed that about 40 percent of the
participants quit smoking with varenicline, compared with 29 percent
with placebo, researchers report in the Canadian Medical Association
Journal.
“These patients are at high risk for recurrent cardiovascular events
(e.g., heart attacks, unstable angina, and mortality) if they
continue to smoke,” said lead study author Sarah Windle of Jewish
General Hospital in Montreal.
While some previous research has linked varenicline to an increased
risk of heart or psychiatric problems, the current study didn’t find
these side effects.
“Our findings suggest that varenicline is efficacious and safe for
smoking cessation in this important patient population,” Windle said
by email.
“Of the first-line treatments used for smoking cessation, which also
include various forms of nicotine replacement therapy and the
prescription medication bupropion, varenicline is the most
effective,” said Robert Reid of the University of Ottawa Heart
Institute. Reid, author of an accompanying editorial, has received
fees from Pfizer, maker of varenicline, and Johnson and Johnson,
maker of various nicotine replacement products.
One advantage of the drug is that it dulls the effect of nicotine in
the brain, making cigarettes less pleasurable. Nicotine replacement
therapies, or e-cigarettes containing nicotine, may help reduce
withdrawal by delivering smaller amounts of nicotine than
traditional cigarettes, Reid said by email.
“The vast majority of smokers have made multiple quit attempts, with
and without assistance and generally have some idea about how they
respond to the currently available treatments,” Reid added. “There
is strong evidence that using these treatments, combined with
behavioral support, makes it significantly more likely that smokers
will be able to achieve long-term abstinence from tobacco.”
SOURCES: http://bit.ly/2pH27f9 Annals of Internal Medicine, online
March 26, 2018, and http://bit.ly/2pJ2xSh Canadian Medical
Association Journal, online March 26, 2018.
[© 2018 Thomson Reuters. All rights
reserved.] Copyright 2018 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |